NEWS
SUBSCRIBER SEARCH (Requires Login)
  NEW DRUGS
  MARKETED DRUGS
  COMPANY
  TARGETS IN ONCOLOGY
  NEWS SUMMARIES
  COMBINATION TRIALS

Latest Updates

First Quarter 2010 Targets in Oncology Updates and Additions

  • 3-Phosphoinositide-dependent kinase-1 (PDPK1)
  • Androgen receptor (Ar)
  • Bombesin receptor family
  • Breast Cancer 1 (BRCA1)
  • CREB regulated transcription coactivator 2 (CRTC2)
  • Cyclin D binding myb-like transcription factor 1 (DMTF1)
  • Dickkopf (DKK) family
  • Forkhead box A1 (FOXA1)
  • Forkhead box M1 (FOXM1)
  • Heat shock 70kDa protein 5 (HSPA5)
  • Histone deacetylase 6 (HDAC6)
  • Hypoxia inducible factor 1 alpha (HIF1A)
  • Protein phosphatase 1D magnesium-dependent, delta isoform (PPM1D)
  • Protein tyrosine kinase 2 beta (PTK2B)
  • CD200
  • Connective tissue growth factor (CTGF)
  • Delta-like 4 (DLL4)
  • EGF-like-domain, multiple 7 (EGFL7)
  • Lamin A/C (LMNA)
  • Mixed lineage leukemia (MLL)
  • Murine double minute 2 (MDM2)
  • Myeloid differentiation primary response gene 88 (MyD88)
  • Neuropilin 1 (NRP1)
  • Notch family
  • Oncostatin M (OSM)
  • Prostate stem cell antigen (PSCA)
  • Seven in absentia homolog-1 (SIAH1)
  • Toll-like receptor 9 (TLr9)
  • V-raf murine sarcoma viral oncogene homolog B1 (BRAF)

     

  

Home   |    Freelance Opportunities   |   New Medicine   |   Site Map   |  Order/Inquiry   
SUBSCRIBER SEARCH:   NEW DRUG   |   MARKETED DRUG   |   COMPANY   |   TARGETS IN ONCOLOGY  

NEW MEDICINE, INC.
P.O. BOX 909, LAKE FOREST, CA 92609
PHONE:  1-949-830-0448     FAX:  1-949-830-0887
INFO@NEWMEDINC.COM